8-K: Nutriband Receives Notice of Allowance for U.S. Patent Covering Abuse-Deterrent Transdermal Technology

Nutriband Inc. has received a Notice of Allowance from the USPTO for its patent application covering Aversa abuse deterrent technology, potentially leading to the issuance of a U.S. patent.

Summary

• Nutriband Inc. announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025, for patent application 18/369,241, which covers its Aversa abuse deterrent technology.
• The Notice of Allowance indicates that the USPTO is expected to issue a U.S. patent for this application after administrative processes are completed.
• The Aversa technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.
• Nutriband's lead product under development is Aversa Fentanyl, an abuse deterrent fentanyl transdermal system, which could be the first abuse deterrent pain patch on the market.
• Aversa Fentanyl has the potential to reach peak annual U.S. sales of $80 million to $200 million.

Sentiment

Score: 7

Explanation: The announcement is positive due to the progress in securing patent protection for the Aversa technology, which could lead to future revenue generation. However, the company still faces risks related to product development, regulatory approvals, and market acceptance.

Positives

• The Notice of Allowance strengthens Nutriband's intellectual property protection in the United States.
• Aversa technology addresses a critical need for abuse-deterrent transdermal products.
• Aversa Fentanyl has significant market potential, with estimated peak annual U.S. sales of $80 million to $200 million.
• The technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries.

Risks

• The actual issuance of the patent is still pending completion of administrative processes.
• The development and commercialization of Aversa Fentanyl are subject to regulatory approvals and market acceptance.
• The forward-looking statements are subject to risks and uncertainties, including the company's ability to develop and market its products, obtain financing, and navigate competition.

Future Outlook

The company anticipates the issuance of a U.S. patent for its Aversa technology and is focused on developing and commercializing Aversa Fentanyl, an abuse-deterrent fentanyl transdermal system.

Industry Context

The development of abuse-deterrent technologies is a significant trend in the pharmaceutical industry, driven by the need to combat opioid abuse and misuse. Nutriband's Aversa technology addresses this need by incorporating aversive agents into transdermal patches.

Comparison to Industry Standards

• Several companies are developing abuse-deterrent formulations of opioids, including Purdue Pharma, Teva Pharmaceutical, and Pfizer.
• These companies are developing abuse-deterrent formulations of opioids, including Purdue Pharma, Teva Pharmaceutical, and Pfizer.
• Unlike oral medications, Nutriband's Aversa technology focuses on transdermal patches, potentially offering a unique approach to abuse deterrence.
• The estimated peak annual sales of $80 million to $200 million for Aversa Fentanyl would position it as a significant player in the abuse-deterrent opioid market, assuming successful development and commercialization.

Stakeholder Impact

• Shareholders: Positive news regarding intellectual property protection.
• Patients: Potential access to a safer abuse-deterrent pain patch.
• Pharmaceutical Industry: Introduction of a new technology to combat opioid abuse.

Next Steps

• Complete the administrative processes required for the USPTO to issue the U.S. patent.
• Continue development and clinical testing of Aversa Fentanyl.
• Seek regulatory approvals for Aversa Fentanyl in the United States and other countries.
• Prepare for the commercial launch of Aversa Fentanyl, pending regulatory approvals.

Key Dates